Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 21 articles:
HTML format



Single Articles


    June 2021
  1. GU S, Lheureux S, Sayad A, Cybulska P, et al
    Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    January 2021
  2. XIAO Y, Lin FT, Lin WC
    ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    December 2020
  3. IWAHASHI N, Ikezaki M, Nishikawa T, Namba N, et al
    Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
    Proc Natl Acad Sci U S A. 2020;117:33225-33234.
    PubMed     Abstract available


  4. KIM O, Park EY, Kwon SY, Shin S, et al
    Targeting progesterone signaling prevents metastatic ovarian cancer.
    Proc Natl Acad Sci U S A. 2020 Dec 1. pii: 2013595117.
    PubMed     Abstract available


    September 2020
  5. SHON DJ, Malaker SA, Pedram K, Yang E, et al
    An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.
    Proc Natl Acad Sci U S A. 2020;117:21299-21307.
    PubMed     Abstract available


    August 2020
  6. HABER T, Cornejo YR, Aramburo S, Flores L, et al
    Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles.
    Proc Natl Acad Sci U S A. 2020;117:19737-19745.
    PubMed     Abstract available


    July 2019
  7. HEYDE A, Reiter JG, Naxerova K, Nowak MA, et al
    Consecutive seeding and transfer of genetic diversity in metastasis.
    Proc Natl Acad Sci U S A. 2019;116:14129-14137.
    PubMed     Abstract available


    March 2019

  8. Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    Proc Natl Acad Sci U S A. 2019 Mar 11. pii: 1902633116.
    PubMed    


    February 2019
  9. WU X, Luo Q, Zhao P, Chang W, et al
    MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 4. pii: 1814742116.
    PubMed     Abstract available


    January 2019
  10. ZHAO Y, Cao J, Melamed A, Worley M, et al
    Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
    Proc Natl Acad Sci U S A. 2019 Jan 18. pii: 1818357116.
    PubMed     Abstract available


  11. GARTUNG A, Yang J, Sukhatme VP, Bielenberg DR, et al
    Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.
    Proc Natl Acad Sci U S A. 2019 Jan 15. pii: 1803999116.
    PubMed     Abstract available


    December 2018
  12. LI C, Bonazzoli E, Bellone S, Choi J, et al
    Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    Proc Natl Acad Sci U S A. 2018 Dec 24. pii: 1814027116.
    PubMed     Abstract available


    June 2018
  13. SUN X, Wang X, Tang Z, Grivainis M, et al
    Transcription factor profiling reveals molecular choreography and key regulators of human retrotransposon expression.
    Proc Natl Acad Sci U S A. 2018;115:E5526-E5535.
    PubMed     Abstract available


    May 2018
  14. SEO A, Steinberg-Shemer O, Unal S, Casadei S, et al
    Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
    Proc Natl Acad Sci U S A. 2018;115:5241-5246.
    PubMed     Abstract available


    March 2018
  15. DI MODUGNO F, Caprara V, Chellini L, Tocci P, et al
    hMENA is a key regulator in endothelin-1/beta-arrestin1-induced invadopodial function and metastatic process.
    Proc Natl Acad Sci U S A. 2018;115:3132-3137.
    PubMed     Abstract available


  16. PATIL P, Parmigiani G
    Training replicable predictors in multiple studies.
    Proc Natl Acad Sci U S A. 2018;115:2578-2583.
    PubMed     Abstract available


  17. PURAYIL HT, Daaka Y
    beta-Arrestin1 mediates hMENA expression and ovarian cancer metastasis.
    Proc Natl Acad Sci U S A. 2018 Mar 7. pii: 1802643115.
    PubMed    


    December 2017
  18. STONE ML, Chiappinelli KB, Li H, Murphy LM, et al
    Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
    Proc Natl Acad Sci U S A. 2017 Dec 4. pii: 1712514114.
    PubMed     Abstract available


    August 2017
  19. KODAMA M, Kodama T, Newberg JY, Katayama H, et al
    In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
    Proc Natl Acad Sci U S A. 2017 Aug 15. pii: 201705441.
    PubMed     Abstract available


    January 2017
  20. TANG Z, Steranka JP, Ma S, Grivainis M, et al
    Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer.
    Proc Natl Acad Sci U S A. 2017 Jan 17. pii: 201619797.
    PubMed     Abstract available


    April 2016
  21. MENGHI F, Inaki K, Woo X, Kumar PA, et al
    The tandem duplicator phenotype as a distinct genomic configuration in cancer.
    Proc Natl Acad Sci U S A. 2016;113:E2373-82.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: